| Objective To explore the clinical features and the outcome of 131I treatment in postoperative patients with middle-high-risk papillary thyroid carcinoma. Methods A total of 104 patients with papillary thyroid carcinoma who underwent 131I ablation treatment in the First Affiliated Hospital of University of Science and Technology of China from May 2017 to October 2019 were selected, and their postoperative clinical data were retrospectively analyzed. All patients received a second 131I treatment or diagnostic 131I whole-body scan at eight to twelve months after the first dose 131I treatment. The therapeutic response was evaluated on the basis of 131I scan, thyroglobulin and other imaging examinations. The data was statistically analyzed, and the results were divided into excellent response, acceptable response, and incomplete response. Single factor analysis and multivariate logistic regression analysis were conducted on the clinical characteristics of patients. Results Single factor analysis showed that there were statistically significant differences in the diameter of the primary tumor (>2 cm, 1~2 cm, <1 cm), the number of lesions (single, multiple), thyroid cancer complications (chronic lymphocytic thyroiditis, nodular goiter, other, none), and the number of cervical lymph node metastases (<5, 5~10, ≥ 11). Multivariate logistic regression analysis showed that the diameter of the primary tumor (<1 cm), and the number of cervical lymph node metastases (<5, 5~10) are independent influencing factors for the clinical outcome of thyroid cancer after 131I treatment. Conclusions The diameter of the primary tumor (<1 cm), and the number of cervical lymph node metastases (<5, 5~10) are independent influencing factors for the clinical outcome of thyroid cancer after 131I treatment. They were closely related to clinical outcomes. |
